|
AU2372699A
|
|
Gro genes, proteins, and uses thereof
|
|
US6238891B1
|
|
Method of increasing product expression through solute stress
|
|
EP0749494A1
|
|
Compositions for the inhibition of tnf formation and uses thereof
|
|
US5538868A
|
|
Recombinant ricin toxin fragments
|
|
US5508031A
|
|
Method for treating biological damage using a free-radial scavenger and interleukin-2
|
|
US5556620A
|
|
Use of recombinant colony stimulating factor-1 to enhance wound healing
|
|
US5422105A
|
|
Use of recombinant colony stimulating factor 1
|
|
US5425940A
|
|
Combination therapy using interleukin-2 and tumor necrosis factor
|
|
CA2147466A1
|
|
Interleukin-6 receptor antagonists
|
|
EP0648225A1
|
|
Compositions for the inhibition of protein hormone formation and uses thereof
|
|
CA2136953A1
|
|
A method for using lipoprotein associated coagulation inhibitor to treat sepsis
|
|
AU4025193A
|
|
Humanized C-erbB-2 specific antibodies
|
|
US5573930A
|
|
DNA encoding various forms of colony stimulating factor-1
|
|
EP0607311A1
|
|
Methods and compositions for identifying inhibitors of papilloma virus replication
|
|
BG60657B2
|
|
Human recombinant interleukin-2 muteins
|
|
US5397703A
|
|
Method for generation of antibodies to cell surface molecules
|
|
BG60442B2
|
|
Dna encoding csf-1 and accompanying recombinant systems
|
|
EP0584238A1
|
|
INHIBITOR OF NF-$g(k)B TRANSCRIPTIONAL ACTIVATOR AND USES THEREOF
|
|
BG60510B2
|
|
Structural genes, plasmides and transformed cells for the production of cystein-poor muteins of biologically active proteins
|
|
BG60506B2
|
|
Human recombinant interleukin-2-mutien
|
